Shaily Engineering Plastics (501423) Q4 24/25 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 24/25 earnings summary
20 Aug, 2026Executive summary
Achieved highest ever consolidated revenues and profitability in FY25, with 22% YoY revenue growth to INR 787 crores and EBITDA margin expanding by 350 bps to 22.7%, driven by strong growth across all business segments and successful ramp-up of new projects.
Healthcare segment revenue surged 53% YoY to INR 165 crores, now 21% of total revenue, driven by IP-led pen platforms and new customer contracts.
Consumer segment revenue grew 17% YoY to INR 561 crores, with new product launches and improved carbon steel business.
Industrial segment revenue increased 12% YoY to INR 61 crores, supported by new automotive component contracts.
Expanded product portfolio and customer base, with multiple new contracts and business awards in Q4 FY25.
Financial highlights
FY25 consolidated revenue at INR 786.8 crores, up 22% YoY; EBITDA at INR 178.4 crores, up 45% YoY; PAT at INR 93.1 crores, up 63% YoY; Q4 FY25 revenue at INR 217.8 crores, up 28% YoY; EBITDA at INR 54.6 crores, up 51% YoY; PAT at INR 28.6 crores, up 48% YoY.
Gross profit margin improved by 470 bps to 47.2% in FY25.
PAT margin improved to 11.8% (+90 bps YoY); cash PAT at INR 135.3 crores, up 45% YoY.
ROCE at 24.4% and ROE at 18.5% as of March 31, 2025.
Debt to equity at 0.4x; long-term debt to equity at 0.07x.
Outlook and guidance
Healthcare segment expected to comprise 30% of revenues in coming years, with continued focus on IP-led devices and contract manufacturing.
Pen manufacturing capacity to expand by 40-50 million units over 18-24 months, targeting 80-90 million total capacity.
Commercial supplies of pens for GLP-1 drug 'Semaglutide' to start in FY26; pen sales projected at ~30 million, with 70% growth driven by IP-led platforms.
New business from global retail chains and marquee FMCG customers to commence in FY26.
No formal company-wide revenue guidance, but management anticipates strong growth and margin improvement year-over-year.
Latest events from Shaily Engineering Plastics
- Q1 FY27 revenue up 14%, healthcare sales surged 85%, and margins expanded.501423
Q1 26/27 - Q1 FY25 saw 14% revenue growth, higher margins, and strong profit momentum across key segments.501423
Q1 24/25 - Strong revenue and margin growth, robust exports, and major capacity expansions underway.501423
Q2 24/25 - Q3 FY25 saw strong revenue, profit, and margin growth, led by healthcare and new contracts.501423
Q3 24/25 - Q1 FY26 revenue rose 38% year-over-year, driven by healthcare growth and margin expansion.501423
Q1 25/26 - Healthcare-led growth and margin expansion drove strong revenue and profit gains.501423
Q2 25/26 - Healthcare-led growth, margin expansion, and major capacity investments drove strong results.501423
Q3 25/26 - Healthcare-led growth drove 26% revenue and 83% PAT surge, with a ₹3 dividend recommended.501423
Q4 25/26